Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

FierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumble

Endpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

Endpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc Live

Endpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

BioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

FierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continues

FierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Endpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustration

Endpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdraw

FierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi Japan

FierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breach

CellBringing the genetically minimal cell to life on a computer in 4D